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Effect on weight gain of routinely giving albendazole to preschool
children during child health days in Uganda: cluster randomised
controlled trial
Harold Alderman, Joseph Konde-Lule, Isaac Sebuliba, Donald Bundy, Andrew Hall
Abstract
Objective To estimate the effectiveness of delivering an
anthelmintic through a community child health programme on
the weight gain of preschool children in Uganda.
Design Cluster randomised controlled trial.
Setting Eastern Uganda.
Participants 48 parishes participating in a new programme for
child health: 24 offered children an additional service of
anthelmintic treatment. The outcome is based on
measurements from 27 995 children.
Intervention Treatment of children aged between 1 and 7 years
with 400 mg albendazole added to standard services offered
during child health days over a three year period.
Main outcome measure Weight gain.
Results The provision of periodic anthelmintic treatment as a
part of child health services in Uganda resulted in an increase
in weight gain of about 10% (166 g per child per year, 95%
confidence interval 16 to 316) above expected weight gain
when treatments were given twice a year, and an increase of 5%
when the treatment was given annually.
Conclusion Deworming of preschool children in Uganda as
part of regularly scheduled health services seems practical and
associated with increased weight gain.
Introduction
Many children in low income countries are commonly infected
with parasitic helminths and this can have important
consequences for their development.1 Infections are easily
treated with inexpensive, single dose oral drugs.2–4 A recent study
of deworming children during home visits in rural Zanzibar
indicated that the youngest children, who are most at risk of
growth retardation, showed the greatest increase in growth rate
after treatment with anthelmintics.5 Home delivery of treatments
may not be a practical and sustainable intervention, however, and
periodic mass deworming without diagnosis, as recommended
by the World Health Organization in areas with more than 50%
of children infected, may be needed to have an effect on growth
during a programme or community health project.
The Ugandan government has established a community
based programme of regular child health days during which
simple health and nutrition interventions are delivered to
preschool children. We assessed whether including anthelmintic
treatment in such a programme at scale could result in
additional weight gain in young children.
Participants and methods
As a part of a nutrition and early child development project in 25
districts of Uganda, the parents of all children aged less than 7
years were offered a range of health services at child health days,
including vaccinations, vitamin A supplements, growth monitor-
ing and promotion, and demonstrations of complementary
feeding. These services were delivered by community organisa-
tions that were supervised by non-governmental organisations
acting as subcontractors in each district.
The study was a cluster randomised effectiveness trial in
which the unit of randomisation was the parish, the administra-
tive unit at which child health days were organised within each
district. Five districts in the eastern region of Uganda were
selected (Busia, Iganga, Mbale, Palissa, and Tororo) because a
survey had indicated that about 60% of children aged 5-10 years
were infected with intestinal nematodes, most commonly
hookworm.6 Fifty parishes selected by the local governments
were randomly allocated into two groups (figure): The randomi-
sation was done by a member of the research team (HA) by
assigning numbers to all of the parishes and converting these to
base two and then determining which of the parishes were to be
in the treatment by coin flips. Twenty five were assigned to stand-
ard services and 25 to standard services plus treatment with
albendazole. One parish from each group was subsequently
removed from the project by district officials and was not
replaced. Albendazole was offered as one 400 mg chewable tab-
let (Zentel: GlaxoSmithKline) to all healthy children aged 1-7
years who attended any child health day. Sick children were not
treated. Parents could refuse albendazole or any other service. As
anthelmintics were not then a standard treatment offered by the
government, they were not provided in the other parishes, which
thus constituted the control group. We included a stopping rule
in the study design; if a statistically significant extra weight gain
occurred by the third round of child health days, albendazole
would be given to all children.
We obtained the date of birth from the growth monitoring
card of each child or from the caregiver. Weight was measured at
each child health day to a precision of 100 g using Unicef scales.
Height was measured to a precision of 1 cm for children older
than 2 years. This information was recorded on a parish register
by staff as part of their normal duties and later transcribed by
research staff, who gave each child a unique identification code
to track them over time. This separation of the programme from
Additional information on statistical analysis is on bmj.com
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research served to minimise the influence of the study on child
health days. To increase compliance the children were not visited
at home.
It was not possible for us to carry out a double blind trial
because of the scale of the programme and because we aimed to
assess the effectiveness of giving albendazole—the efficacy of
which was already established—during standard child health
days without any study specific inputs. We considered the possi-
bility of a Hawthorne effect unlikely as the child health days were
new for both treatment and control groups and the primary out-
comes were determined objectively for all children as a part of
normal growth monitoring by programme staff.
To assess programme coverage and the use of anthelmintics
not given by the programme, we carried out cluster surveys of
households in all parishes during the first quarter of 2000 and
2003. Two villages were randomly selected in each parish, a
household census was done, and 1500 households (750 in each
group) containing at least one child aged less than 6 years, were
randomly selected. Each household was located with a satellite
global positioning system to facilitate follow up.We administered
a questionnaire between January and March 2000. Each
caregiver was asked if the child had been treated for worms, from
where the treatment had been obtained, and how much the
treatment had cost. Each household was revisited between Janu-
ary and March 2003 and the questionnaire was repeated.
Non-compliance was less than 2%.
The main outcome measure was weight gain, calculated as
the difference in weight between the first and last child health
day for each child. We excluded from the analysis any measure-
ment six or more standard deviations above or below reference
weight for age. This is a more inclusive definition of outliers than
recommended by WHO7 and reduced the sample size by 1.8%
(260 children in the control group and 253 in the treatment
group). We used EpiInfo to calculate Z scores of weight for age
and height for age, which uses the National Center for Health
Statistics reference values recommended by WHO.
As the effect of treatment with albendazole on weight gain is
likely to be related to personal and environmental factors, we
controlled for these by using multivariate regression models in
Stata. These factors were the number of albendazole treatments
received, so we included in the model the number of visits to
child health days by children in both groups; the sex of the child;
the age, weight, and initial nutritional status of the child at
recruitment, as these all can influence subsequent weight gain;
the period between the first and last measurements, as this will
affect total weight gained; the parish, as the local environment
can affect food production and disease transmission; the district
in which the parish was located, and, finally, the round, to control
for seasonal food production and disease transmission. We also
examined alternative models. In one, initial weight was replaced
by initial weight predicted from height, sex, and age, because ini-
tial weight was correlated with the outcome measure, weight
gain. In another model, we examined weight gain per month as
an alternative to absolute weight gain. (See bmj.com for further
details of the statistical models and sensitivity analysis.) As some
children attended more child health days than others and
received more treatments with albendazole, in a portion of the
analysis we divided the treatment group into three based on
intervals between attendance: 7.5 months or less, 7.5-13 months,
and more than 13 months. Although this is not an equal division
of the sample (it represents 18%, 67%, and 15% of the treatment
group, respectively) these intervals corresponded to practical
targets of biannual, annual, or less frequent treatment during a
programme, with slight delays typical of programmes, and were
used to indicate the potential benefit of treatments given at those
frequencies.
Results
The study was undertaken between November 2000 and June
2003 during which five child health days occurred in each parish.
Because of a delay in funding, almost 12 months, rather than 6
months, elapsed between the first two child health days. Table 1
presents descriptive statistics on the child health days and the
percentage of children classified as underweight at each round.
The absence of any apparent difference in the percentage of
underweight children or in the mean Z scores between the treat-
ment and control groups does not indicate the absence of an
effect, as new children entered the project and study at each
round, whereas others did not always attend.
Table 2 shows that at least two measurements of body weight
were made on 14 940 treated children and 13 055 control
children, and that there was a statistically significant difference in
extra weight gained of 154 g (95% confidence interval 96 to 214,
P < 0.01). This is equivalent to an extra 166 g per year (16 to 316
g) or nearly 10% of average initial body weight.
Table 3 shows the results of six regression models, five using
total weight gain and the sixth using weight gain per month.
Model 1 indicates that weight gain was greater in children who
attended more child health days but that children in the parishes
where albendazole was given gained 55 g (9 to 104 g) more
weight per visit than children in control parishes. The robustness
of this model was then tested in other models.
Model 2 shows that the interval between the first and last
measurements was highly correlated with total weight gain, as
expected, but the difference in total weight gain per visit between
study groups did not change although the magnitude of both did
change.
Model 3 shows the effect of attending child health days in
which the treatment effect is divided into three groups: about
twice a year, annually, or at a longer interval. The children treated
twice a year gained more weight than children treated less often.
Model 4 controls for initial weight. No biological interpreta-
tion can be assigned to the coefficient of initial weight in this
model since any measurement error in the initial weight is also in
the dependent variable, total weight gain, leading to a bias
Parishes in five districts selected on basis of need (n=50)
Randomised
Parishes allocated to
provision of albendazole at
child health days (n=25)
Parishes allocated to
child health days without
albendazole (n=25)
Allocation
Children with at least two
measurements of
body weight analysed
(n=14 940)
Children with at least two
measurements of
body weight analysed
(n=13 055)
Analysis
All parents attending child
health days offered
albendazole for their
children aged 1-7 years in
addition to standard health
services (child health days
cancelled in one parish)
All parents attending child
health days offered standard
health services for their
children aged 1-7 years
(child health days
cancelled in one parish)
Treatment
Flow chart of study design
Research
page 2 of 5 BMJ Online First bmj.com
towards minus one for that coefficient. This initial weight
variable, however, picks up unexplained variance without biasing
the variable of interest. It indicates that there was no bias.
Model 5 repeats model 4 but uses a value for initial weight
predicted from the height of children aged more than 2 years,
their sex and age, and fixed effects of the parish. This was done
because the initial weight used in model 4 is correlated with the
outcome, gain in weight. The prediction equation had an R2 value
of 0.782. As recumbent length was not recorded for children less
than two years old, not every child weighed had height recorded,
so the sample size was reduced. Neither models 4 nor 5 led to an
appreciable change in variable estimates.
Model 6 uses the variables in model 3, but standardises the
outcome per unit time by using weight gain per month as the
outcome variable. It shows an average additional weight gain of
13.8 g per month among children treated about twice a year, but
it was not significant if the interval between treatments was a year
or more. In model 6 the interval between the first and last meas-
urement was negatively associated with monthly weight gain.
This probably reflects the fact that weight gain declines with age
so that, as the interval between the first and last measurements
increases the longer participants were studied, the velocity of
weight gain decreases. The length of time each child was studied
has a strong correlation with the total weight gain, but not with
weight gain per month.
Table 4 shows that the percentage of households who
reported deworming their children before the programme
Table 1 Dates of child health days in rural Uganda, sample sizes, proportion of children classified as underweight (−2 SD below reference vales), and mean
Z scores of weight for age of children in treatment and control parishes
Variable
Round
1 2 3 4 5
Start of child health days 2 Nov 2000 14 Aug 2001 18 Feb 2002 2 Sep 2002 18 Mar 2003
End of child health days 8 Dec 2000 30 Nov 2001 29 Jun 2002 19 Oct 2002 26 Jun 2003
No of children weighed 37 165 33 711 21 124 20 787 20 443
Percentage of girls 50.0 50.3 50.6 51.1 50.7
Percentage receiving treatment 50.7 51.2 51.9 53.8 56.8
Mean (SD) age (years) 3.69 (1.66) 3.64 (1.80) 3.69 (1.77) 3.63 (1.63) 3.54 (1.54)
Proportion underweight:
Treatment parishes 0.26 0.24 0.23 0.23 0.24
Control parishes 0.26 0.25 0.25 0.23 0.24
Mean (SD) Z scores of weight for age:
Treatment parishes −1.14 (1.48) −1.06 (1.52) −1.07 (1.45) −1.14 (1.32) −1.23 (1.25)
Control parishes −1.17 (1.45) −1.11 (1.52) −1.14 (1.44) −1.17 (1.29) −1.20 (1.25)
Table 2 Average weight gain, months in programme, and number of visits
to child health days in Uganda for all children with two or more
measurements
No of children with repeated
measurements
Treatment
parishes (n=14
940)
Control parishes
(n=13 055) All (n=27 995)
Mean (SD) weight gain (g) 2413 (2536) 2259 (2474) 2341 (2508)
Mean (SD) months in
programme
16.9 (7.7) 16.2 (7.5) 16.6 (7.6)
Mean (SD) visits to child
health days
2.7 (0.9) 2.6 (0.8) 2.7 (0.9)
Table 3 Variables generated by regression models examining effect on weight gain of attendance at child health days in rural Uganda where albendazole was
provided. 95% confidence intervals are corrected for cluster sampling effects
Outcome variable
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Total weight gain (g)
(95% CI)
Total weight gain (g)
(95% CI)
Total weight gain (g)
(95% CI)
Total weight gain (g)
(95% CI)
Total weight gain (g)
(95% CI)
Weight gain per month
(g) (95% CI)
No of visits to treatment site 705.0** (648 to 762) 143.7** (87 to 201) — — — —
No of visits to control site 649.6** (592 to 707) 92.5** (25 to 160) — — — —
Initial age (months) −689.4**
(−790 to −589)
−693.9**
(−791 to −597)
−694.2**
(−797 to −597)
−519.9**
(−603 to −510)
−838.23**
(−955 to −721)
−41.0**
(−48.9 to −33.0)
Age2 (months) 56.5** (43 to 70) 66.3** (54 to 78) 66.3** (54.2 to 78.4) 41.7** (29.8 to 53.6) 78.5** (64.0 to 93.0) 3.8** (2.8 to 4.8)
Interval between first and final
measurement
— 99.0** (89 to 109) 111.6**
(104.6 to 118.7)
102.8** (95.6 to 109.9) 102.0** (93.3 to 110.7) −2.0* (−2.4 to −1.5)
Girls 49.6* (1 to 98) 48.5 (−0.8 to 98) 49.1 (−0.7 to 100) 125.2** (73.0 to 177.3) 101.4** (50 to 153) 1.9 (−2.5 to 6.3)
Treatment if time between
visits ≤7.5 months
— — 158.2** (59.0 to 262.3) 169.5** (52.4 to 286.6) 178.0* (37.3 to 318.6) 13.8* (1.3 to 26.3)
Treatment if time between
visits >7.5 and ≤13 months
— — 106.6* (23.2 to 190.0) 127.7* (30.0 to 225.5) 128.8* (14.8 to 242.8) 6.6* (0.2 to 12.9)
Treatment if time between
visits ≥13 months
— — −125.4 (−304.7 to 53.9) −127.7 to 307.5 to 52.1) −150.6 (−142.5 to 41.0) −4.3 (−13.4 to 4.8)
Initial weight (g) — — — −555.2**
(−600.1 to −510.3)
— —
Initial weight (g, predicted) — — — — −273.3**
(−333.8 to −212.8)
—
Constant 2684** (2452 to 2915) 1853** (1581 to 2124) 1801** (1524 to 2078) 911** (668 to 1154) 1917** (1625 to 2208) 257** (235 to 280
No of children 27 995 27 995 27 995 27 995 21 134 27 995
R2 0.146 0.178 0.178 0.283 0.183 0.018
Constant is average of fixed effects.
*Coefficient differs from zero (two tailed test) with P≤0.05.
**Coefficient differs from zero (two tailed test) with P≤0.01.
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started in 2000 was similar in both treatment and control
parishes. By 2003 three times as many children in the treatment
parishes had been dewormed,mostly at the child health days, but
this practice had also increased by 50% in the control parishes.
Most treatments for the control group were obtained from
private clinics or shops, where the average cost was Ugandan
shillings (USH) (SD 705) 748 or about £0.20 (€0.30, $0.40). No
significant difference was found in the average number of child
health days attended by children in the treatment and control
parishes.
Discussion
Periodic treatment with albendazole given twice a year as a part
of child health services in Uganda led to a 10% extra gain in
weight of about 166 g per child per year compared with
untreated controls, or an extra weight gain of around 5% if chil-
dren were treated annually. This study involved nearly 30 000
children taking part in a national programme, and the data were
collected as a part of routine growth monitoring to minimise the
effect of the study on implementation. The effect of treatment
may have been underestimated because about a third of children
in the control parishes were also dewormed by their parents
(table 4). As the predominant intestinal helminth in the districts
was hookworm, and infections in young children in the same
districts were generally light,8 a greater effect of treatment may be
achieved elsewhere.
The research design did not permit determining if other
health services complement the provision of albendazole.
Moreover, as compliance was estimated to be 73%, it is not pos-
sible to generalise these results to the total population of
children.
A meta-analysis of deworming children and young people
aged up to 16 years9 found a similar magnitude of extra weight
gain, but the lack of consistency in trial design and follow-up
period in these studies makes it premature to conclude that this
is a general finding. A review of randomised trials of
anthelmintic treatment given to preschool children—the age
group in our study—found that growth was improved in four tri-
als, was unaffected in four, and had an inverse relation to
treatment in one.5 Although only one study reviewed showed an
increase in linear growth, all four of the trials with positive results
reported benefits in ponderal growth, as in our study. The meta-
analysis pointed out that most studies have been done in popu-
lations infected with Ascaris lumbricoides, but the largest effect on
weight gain in preschool children has been in populations
infected predominantly with Trichuris or hookworm, as in our
study.
Deworming has benefits beyond those measured in our
study. These include effects on anaemia, cognitive development,
and possible improvements of vitamin A status,10 11 as well as
spillover outside the treated group as a result of reduced
transmission. Treating children alone can reduce the prevalence
of worms among untreated people12 and provide measurable
benefits for untreated populations.13
On average, child health days in Uganda cost between $500
and $600 per event, exclusive of the value of the time of commu-
nity volunteers, and slightly more when days included a demon-
stration of how to prepare food. On average each event reaches
450 children, suggesting a cost for services delivered of about $1
to $1.33 per child. The direct resource cost per child is similar to
delivering vitamin A with polio inoculations in other countries14
and similar to programmes to treat helminths.1
A single dose of albendazole added $0.21 (USH 385) to the
costs of materials at child health days at 2002 prices but added
little to the costs of staff since they were already dispensing vita-
min A. This cost could be substantially reduced, to as low as
$0.03, by bulk purchase of the drug. But even when applying the
actual prices in 2002 and ignoring the other known benefits of
deworming, the 10% increase in weight gain with twice yearly
treatment at a cost of $0.42, or a 5% increase at a cost of $0.21,
represents an attractive return. Shortly after completing this
study the government of Uganda purchased eight million doses
of mebendazole to extend deworming at child health days to the
whole nation.
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Table 4 Proportion of children aged 1 year or older who were reported to have been dewormed in samples of households in two surveys three years apart
in parishes in rural Uganda in which deworming was being provided (treatment) at child health days and in parishes where no deworming was provided
(control)
Round
Treatment parishes Control parishes
Jan-Mar 2000 Jan-Mar 2003 Jan-Mar 2000 Jan-Mar 2003
No of children 1392 1296 1393 1314
% of children dewormed from any source in past six
months
21.7 65.8 23.9 34.6
% getting treatment from private or non-governmental
organisation sources
NA 11.4 NA 15.2
Cost (USH) at private providers NA 748 NA 776
Attended child health day in past two years (yes or no) NA 0.735 NA 0.730
No of child health days attended NA 1.738 NA 1.764
NA=question not asked in first round (child health days not organised in region at time of initial survey). USH=Ugandan shillings.
What is already known on this topic
Clinical trials of anthelmintic treatments have shown
increased linear growth in young people up to age 16 years,
whereas in younger people the increase is mainly in weight
Little evidence exists of the benefits of giving periodic mass
treatment through public health programmes, and none is
targeted at preschool children
What this study adds
Giving anthelmintic treatments routinely as a part of
periodic child health days can lead to extra weight gain in
preschool children in Uganda
The weight gain of children who attended child health days
every six months was 10% greater than in untreated
controls
Research
page 4 of 5 BMJ Online First bmj.com
Funding: The research was funded by the nutrition and early child develop-
ment project, government of Uganda, which contracted the Institute of
Public Health and the research committee of the World Bank. The World
Bank employs HA and DB and contracted AH.
Competing interests: None declared.
Ethical approval: This study was approved by the ethics review committee of
the Institute of Public Health and conforms to human study protocols for
the government of Uganda.
1 Awasthi S, Bundy DAP, Savioli L. Helminthic infections. BMJ 2003;327:431-3.
2 Bundy DAP, Guyatt HL. Schools for health: focus on health, education and the school-
aged child. Parasitol Today 1996;12:1-16.
3 Hotez P, Bundy DAP, Beegle K, Brooker S, Drake L, De Silva N, et al. Helminth infec-
tions: soil-transmitted helminth infections and schistosomiasis. Chapter 24.Disease con-
trol priorities for developing countries. In: Jamison D, Claeson M, Breman J, Meacham A,
eds. Oxford: Oxford University Press, 2005.
4 Stephenson LS, Latham MC, Adams EJ, Kinoti SN, Pertet A. Weight gain of Kenyan
school children infected with hookworm, Trichuris trichiura and Ascaris lumbricoides
is improved following once- or twice-yearly treatment with albendazole. J Nutr
1993;123:656-65.
5 Stoltzfus RJ, Chway H, Montresor A, Tielsch JM, Jape JK, Albonico M, et al. Low dose
daily iron supplementation improves iron status and appetite but not anemia, whereas
quarterly anthelminthic treatment improves growth, appetite and anemia in Zanzibari
preschool children. J Nutr 2004;134:348-56.
6 Kabatereine N, Tukahebwa E. Brooker S, Alderman H, Hall A. Epidemiology of intes-
tinal helminth infections among schoolchildren in southern Uganda. East Afr Med J
2001;78:283-6.
7 World Health Organization. Physical status: the use and interpretation of anthropometry.
WHO technical report series 854. Geneva: WHO, 1995.
8 World Health Organization. Prevention and control of schistosomiasis and soil-transmitted
helminthiasis. Report of a WHO expert committee. WHO technical report series 912.
Geneva: WHO, 2002.
9 Dickson R, Awasthi S, Williamson P, Demellweek C, Garner P. Effect of treatment for
intestinal helminth infection on growth and cognitive performance in children:
systematic review of randomized trials. BMJ 2000;320:1697-701.
10 Bundy DAP, Shaeffer S, Jukes M, Beegle K, Gillespie A, Drake L, et al. School based
health and nutrition programs. Chapter 61. Disease control priorities for developing coun-
tries. In: Jamison D, Claeson M, Breman J, Meacham A, eds. Oxford: Oxford University
Press, 2005.
11 Jalal F, Neisheim M, Agus Z, Sanjur D, Habicht J-P. Serum retinol concentrations in
children are affected by food sources of -carotene, fat intake, and anthelmintic drug
treatment. Am J Clin Nutr 1998;68:623-9.
12 Bundy DAP, Wong MS, Horton J. Control of geohelminths by delivery of targeted
chemotherapy through schools. Trans R Soc Trop Med Hyg 1990;84:115-20.
13 Miguel E, Kremer M. Worms: identifying impacts on education and health in the pres-
ence of treatment externalities. Econometrica 1004;72:159-217.
14 Goodman T, Dalmiya N, de Benoist B, Schultink W. Polio as a platform: using national
immunization days to deliver vitamin A supplements. Bull World Health Organ
2000;78:305-14.
(Accepted 24 March 2006)
doi 10.1136/bmj.38877.393530.7C
World Bank, Washington DC 20433, USA
Harold Alderman lead human development economist
Donald Bundy lead specialist
Institute of Public Health, Makerere University, Kampala, Uganda
Joseph Konde-Lule professor of epidemiology
Isaac Sebuliba research fellow
Centre for Public Health Nutrition, School of Integrated Health, University of
Westminster, London W1W 6UW
Andrew Hall partnership for child development
Correspondence to: H Alderman halderman@worldbank.org
Research
BMJ Online First bmj.com page 5 of 5
